[Ip-health] Peter Bach in Forbes - Cancer: Unpronounceable Drugs, Incomprehensible Prices

Jamie Love james.love at keionline.org
Thu Aug 14 15:36:03 PDT 2014


>From Peter Bach's blog in Forbes.

------------------------
*  Zykadia, Novartis’ pill for a sub-type of lung cancer caused by a defect
in the Alk gene, approved by the FDA in April of this year.  The company
charges $13,200 per month for it.

*  Its competitor is the older drug Xalkori, Pfizer’s pill that has the
same mechanism of action and targets the same type of lung cancer.
 Approved in 2011, it costs $11,500 per month.

*  The industry talks about the risk that a drug they develop may not work.
 True, there are large risks, as clinical research often fails to pan out.
 Novartis took that risk with Zykadia. But Zykadia is a me-too drug.
 Xalkori, the drug it imitates, was the first of its kind.  So whatever
Novartis’ risk, Pfizer’s was greater.  Yet Zykadia costs more.

*  So, we’re left with only one explanation that actually fits the data,
and it’s mine.  The pricing of Zykadia has nothing to do with what it took
to bring it to market, it has to do with when it came on the market.
 Today’s tolerance for high drug prices is just greater than it was three
years ago and much greater than it was a decade ago when the median price
of cancer drugs was about $5,000 per month (in today’s dollars).


Forbes http://onforb.es/1mJmnTc

Cancer: Unpronounceable Drugs, Incomprehensible Prices

Comment Now

GUEST POST WRITTEN BY
Peter Bach
Director, Center for Health Policy and Outcomes

Cancer drug prices keep rising.  The industry says this reflects the rising
costs of drug development and the business risks they must take when
testing new drugs.  I think they charge what they think they can get away
with, which goes up every year.

 [bach chart]

Let’s consider the two arguments, and how the latest new drug for lung
cancer supports each.

The drug is Zykadia, Novartis’ pill for a sub-type of lung cancer caused by
a defect in the Alk gene, approved by the FDA in April of this year.  The
company charges $13,200 per month for it.  Its competitor is the older drug
Xalkori, Pfizer’s pill that has the same mechanism of action and targets
the same type of lung cancer.  Approved in 2011, it costs $11,500 per
month.   In other words, Zykadia costs almost $2000 more per month.

The industry talks about the risk that a drug they develop may not work.
 True, there are large risks, as clinical research often fails to pan out.
 Novartis took that risk with Zykadia. But Zykadia is a me-too drug.
 Xalkori, the drug it imitates, was the first of its kind.  So whatever
Novartis’ risk, Pfizer’s was greater.  Yet Zykadia costs more.

The industry says that clinical research costs a lot of money because the
FDA requires large human studies.  True.  Novartis had to run a trial of
163 patients to convince the FDA about Zykadia.  But Pfizer had to run two
studies with 255 patients in total.  More studies with more patients means
Pfizer spent more than Novartis on clinical research.  The pricing of the
two drugs suggests the opposite.

The industry cites the challenges of bringing new classes of drugs to the
market.  They have to educate doctors about them and the disease sub-type
they target.  Here again, Pfizer did the work back when few doctors knew
about Alk associated lung cancer.

Three years later Novartis enters a mature and educated market.

In the case of these two drugs, figuring out whether a lung cancer patient
should get either requires determining if a lung cancer patient even has
the defect in the Alk gene.  That requires a special genetic test that did
not exist commercially a few years ago.  So Pfizer (not Novartis) partnered
with Abbott Labs to develop the test in tandem with Xalkori.  The FDA
approved Pfizer’s Xalkori and the test, what experts call a companion
diagnostic, on the same day.  Novartis, well, didn’t have to take on that
task either.

Differences in clinical outcomes in some cases might explain this pricing
paradox, but the two drugs have not been directly compared.  Anyway, the
FDA says Xalkori, not Zykadia, is the first choice for this subgroup of
lung cancer patients.  Zykadia is for what experts call ‘second line
treatment’.  The response rates, a measure of the drug’s effectiveness,
seem about the same.  Side effects are hard to compare, but  a number of
them occur more often with Zykadia – both the minor ones and the life
threatening ones.

So, we’re left with only one explanation that actually fits the data, and
it’s mine.  The pricing of Zykadia has nothing to do with what it took to
bring it to market, it has to do with when it came on the market.  Today’s
tolerance for high drug prices is just greater than it was three years ago
and much greater than it was a decade ago when the median price of cancer
drugs was about $5,000 per month (in today’s dollars).

This rapid rise in prices has put cancer drugs near the top of the list of
growth categories in healthcare spending.  Nearly $30B on cancer drugs last
year, up 9% from the year before.  The phenomenon has bled into other
diseases more recently.  A new drug for cystic fibrosis called Kalydeco
costs $26,000 per month.  It needs to be taken for life.

Gilead’s drug Sovaldi for Hepatitis C is $30,000 a month and $84,000 for a
treatment course. One health executive posited that the annual pricetag for
Sovaldi could reach $300B because so many people have this infection.
 That’s more than all spending on all drugs in the United States currently.
 A more realistic number might be between $7B and $12B a year.  Even that
amount is roughly five times the amount Gilead spends each year on research.

Regardless of the estimate, the pricing of new drugs for cancer and now
other common diseases has come unglued from the rationale the industry has
long espoused.  Instead, pricing is explained by a phenomenon of increasing
boldness by the industry against a backdrop of regulators and insurers who
have no legal authority to dictate or even propose alternative pricing
models.

We are going to have to take some difficult steps, and do so at a time when
the healthcare dialogue is polarized not only over the Affordable Care
Act’s implementation, but over whether or not there is a distinction
between rationality and rationing.

One way forward would be to ensure that when me-too drugs come on the
market, even high priced ones for life threatening diseases, the
manufacturer’s have incentives, and insurers have payment mechanisms, that
support those companies undercutting their competitors on price in order to
gain market share.  Right now our system doesn’t do that, but that’s what a
normal market would look like.

Or we could stick with the current expensive model, in which case we should
ask the drug industry to connect the dots for us between the societal goals
they aim to achieve, the costs they incur, and the profits they should
reasonably be earning.   They might as well start by explaining why Zykadia
costs more than Xalkori.

Dr. Bach is The Director of Memorial Sloan Kettering’s Center for Health
Policy and Outcomes. His work is regularly featured in major scientific and
lay press outlets such as the NEJM, JAMA, and the New York Times. Dr. Bach
is a member of the Institute of Medicine’s Board on Health Care Services
and National Cancer Policy Forum and the Committee on Performance
Measurement of the National Committee on Quality Assurance.

This article is available online at: http://onforb.es/1mJmnTc2014
Forbes.com


-- 
James Love.  Knowledge Ecology International
http://www.keionline.org, KEI DC tel: +1.202.332.2670, US Mobile:
+1.202.361.3040, Geneva Mobile: +41.76.413.6584,   twitter.com/jamie_love



More information about the Ip-health mailing list